(Q41689265)

7 October 2017

title

Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes (English)

1 reference

7 October 2017

2

H W Flynn

1 reference

7 October 2017

P D Weishaar

1

1 reference

7 October 2017

T G Murray

3

1 reference

7 October 2017

J L Davis

4

1 reference

7 October 2017

C C Barr

5

1 reference

7 October 2017

J G Gross

6

1 reference

7 October 2017

C E Mein

7

1 reference

7 October 2017

W C McLean

8

1 reference

7 October 2017

J H Killian

9

1 reference

7 October 2017

publication date

1 January 1998

1 reference

7 October 2017

1 reference

7 October 2017

volume

105

1 reference

7 October 2017

issue

1

1 reference

7 October 2017

page(s)

57-65

1 reference

Endogenous Candida endophthalmitis. Management without intravenous amphotericin B

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Endogenous Aspergillus Endophthalmitis Occurring After Kidney Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Endogenous Aspergillus uveitis following heart surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Endogenous Aspergillus endophthalmitis after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Aspergillus terreus endophthalmitis in a patient with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Bilateral endogenous Aspergillus endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Metastatic Endophthalmitis Associated with Injection of Addictive Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Endogenous Aspergillus endophthalmitis in drug abusers

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Invasive aspergillosis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Aspergillus species colonization and invasive disease in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Aspergillosis in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Macular pseudohypopyon from secondary syphilis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Endogenous aspergillus endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Treatment and developmental therapeutics in aspergillosis. 1. Amphotericin B and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Penetration of amphotericin B into the human eye

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Comparison of Azoles against Aspergilli in vitro and in an Experimental Model of Pulmonary Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Toxicity of Intravitreal Injection of Amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2971225-3

7 January 2021

10.1016/S0161-6420(98)71225-3

Identifiers

DOI

1 reference

7 October 2017

1 reference